Share
CHICAGO: Getz Pharma Malaysia Sdn Bhd, a subsidiary of Getz Pharma (Private) Ltd of Pakistan, plans to acquire 15 acres of land for its facility in techpark@enstek, Bandar Enstek Nilai, announced Malaysian Biotechnology Corp (BiotechCorp) at the Malaysian Pavilion at the BIO International Convention here on May 4. BiotechCorp is in charge of facilitating Malaysia's biotechnology industry.
The Pakistani branded generic pharmaceutical company plans to invest up to US$45 million (RM145.62 million) in the facility, which will undertake the research, development, production and commercialisation of sterile injectables, solid dosage, penicillin products and biopharmaceutical products.
The plant will be have standards that are compliant with the US Food and Drug Administration, the Medicines and Healthcare Products Regulatory Agency of the UK and other regulatory agencies.
techpark@enstek is a 524-acre technological hub development in Bandar Enstek under a joint venture between TH Properties Sdn Bhd, the property arm of Tabung Haji, and the Negri Sembilan State Development Corp (PKNNS)
Getz Pharma Malaysia manufactures products that are primarily targeted at highly regulated markets such as in the US, the European Union, Australia, Japan and semi-regulated markets such as Russia. It will also serve the Malaysian and Asean markets.
Getz Pharma Pakistan started operations in 1995 and is a subsidiary of the Getz Group of Companies based in the US. It has manufacturing facilities in Karachi, Pakistan, with a drug development facility in Mumbai, India. Its largest operations are in the Philippines, Vietnam, Pakistan, Afghanistan, Sri Lanka, Kenya, and Central Asia.
